Loading...

FITC anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1.2_FITC_IFNgamma_Antibody_ICFC_1_090712
  • XMG1.2_FITC_IFNgamma_Antibody_ICFC_1_090712
  • XMG1.2_FITC_IFNgamma_Antibody_ICFC_2_090712
See FITC spectral data
Cat # Size Price Save
505805 25 µg ¥7,260
505806 100 µg ¥18,610
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical data sheet

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Onodera A, et al. 2017. J Immunol. 10.4049/jimmunol.1602129. PubMed
  2. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  3. Dar HY, et al. 2018. Sci Rep. 8:2503. PubMed
  4. Dar HY, et al. 2018. Bone Rep. 8:46. PubMed
  5. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  6. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  7. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  8. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  9. Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
  10. Laura C Burzynski et al. 2019. Immunity. 50(4):1033-1042 . PubMed
  11. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  12. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  13. Yang X, et al. 2019. Oncotarget. 10:4180. PubMed
  14. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  15. Nika L, et al. 2019. Vaccines (Basel). 7. PubMed
  16. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  17. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  18. Alessandrini F, et al. 2019. Oncogene. 38:4467. PubMed
  19. Gagnon JD, et al. 2019. Cell Rep. 28:2169. PubMed
  20. Kenichi Shimada et al. 2018. Immunity. 49(5):873-885 . PubMed
  21. Sophie Thiemann et al. 2017. Cell host & microbe. 21(6):682-694 . PubMed
  22. Guo C, et al. 2017. Methods Mol Biol. 1709:345. PubMed
  23. Zhu C, et al. 2018. Sci Rep. 5.113194444. PubMed
  24. Sartorius R, et al. 2018. Front Immunol. 1.413888889. PubMed
  25. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  26. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  27. Magen A, et al. 2019. Cell Rep. 29:3019. PubMed
  28. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  29. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  30. Nakornpakdee Y, et al. 2018. Asian Pac J Allergy Immunol. 36:265. PubMed
  31. Zeng J, et al. 2020. Int J Biol Sci. 1.939583333. PubMed
  32. Cheng Y, et al. 2020. PLoS Pathog. 16:e1008569. PubMed
  33. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  34. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  35. Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed
  36. He J, et al. 2020. Cell Reports. 29(9):2718-2730.e6.. PubMed
  37. Chao CC, et al. 2020. Cell. 179(7):1483-1498.e22.. PubMed
  38. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  39. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  40. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  41. Larena M, et al. 2011. J Virol. 85:5446. PubMed
  42. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  43. Gao X, et al. 2010. Mol Immunol. 47:2397. PubMed
  44. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  45. Brenndörfer E, et al. 2014. J Immunol. 192:1671. PubMed
  46. Kedzierski L, et al. 2014. PLoS Pathog. 10:1004134. PubMed
  47. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  48. Ni P, et al. 2014. J Immunol . 193:1778. PubMed
  49. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  50. Wei F, et al. 2014. Cancer Res. 74:5989. PubMed
  51. Ni P, et al. 2014. Mol Immunol. 62:199. PubMed
  52. White C, et al. 2015. J Immunol. 194:697. PubMed
  53. Weigelin B, et al. 2015. Proc Natl Acad Sci U S A. 112:7551. PubMed
  54. Li Y, et al. 2015. J Nutr Biochem. Available online 8 August 2015. PubMed
  55. Yuan C, et al. 2015. Biochem Biophys Res Commun. 464: 249-255. PubMed
  56. Lebrun A, et al. 2015. J Immunol. 195: 4358 - 4368. PubMed
  57. Pinget G, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.48. PubMed
  58. Sood S, et al. 2016. J Immunol. 197: 429 - 440. PubMed
  59. Zamora-Chimal J, et al. 2017. Immunobiology. 222(2):454-462. PubMed
  60. M H, et al. 2016. Open Bio. 6: 150208. PubMed
  61. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  62. Takahashi T, et al. 2017. J Exp Med. 10.1084/jem.20160247. PubMed
  63. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  64. Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed
  65. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  66. Kim EH, et al. 2020. Elife. 9:00. PubMed
  67. Isakova-Sivak I, et al. 2020. Vaccines (Basel). 8:00. PubMed
  68. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  69. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  70. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  71. Wu B, et al. 2021. Immunity. 54(2):308-323.e6. PubMed
  72. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
  73. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  74. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  75. Stutz MD, et al. 2021. Immunity. 54(8):1758-1771.e7. PubMed
  76. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  77. Huang LJ, et al. 2021. Immunity. 54(8):1728-1744.e7. PubMed
  78. Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed
  79. Wang Z, et al. 2020. Autophagy. 1:. PubMed
  80. Gao Y, et al. 2020. Nat Cell Biol. 1064:22. PubMed
  81. Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed
  82. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  83. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  84. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  85. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  86. Nakazawa S, et al. 2020. Sci Rep. 10:14559. PubMed
  87. Baier FA, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:745. PubMed
  88. Ontiveros-Padilla L, et al. 2021. Microorganisms. 9:. PubMed
  89. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  90. Khakhum N, et al. 2021. NPJ Vaccines. 6:72. PubMed
  91. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
  92. Sato Y, et al. 2021. J Clin Invest. Online ahead of print. PubMed
  93. Ford K, et al. 2020. Cancer Res. 80:1846. PubMed
  94. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  95. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  96. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  97. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  98. Aggarwal N, et al. 2021. Cell Rep. 37:110170. PubMed
  99. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  100. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  101. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  102. Zhang L, et al. 2022. Front Immunol. 13:828263. PubMed
  103. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  104. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  105. Miyauchi E, et al. 2020. Nature. 585:102. PubMed
  106. Pardy RD, et al. 2021. Nat Commun. 12:4051. PubMed
  107. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  108. Li Y, et al. 2021. Elife. 10:. PubMed
  109. Chung NH, et al. 2022. Vaccine. 40:574. PubMed
  110. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  111. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  112. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  113. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  114. Yamazaki S, et al. 2022. Mucosal Immunol. :. PubMed
  115. Yu Y, et al. 2022. iScience. 25:105004. PubMed
  116. Olivo Pimentel V, et al. 2021. J Immunother Cancer. 9:. PubMed
  117. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
  118. Khan IM, et al. 2021. Immunohorizons. 5:703. PubMed
  119. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  120. Pu Y, et al. 2022. Transl Psychiatry. 12:223. PubMed
  121. Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed
  122. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  123. Crooks SD, et al. 2022. Immunohorizons. 6:705. PubMed
  124. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  125. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  126. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
  127. Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed
  128. D'Angeli V, et al. 2022. Eur J Immunol. 52:1058. PubMed
  129. Wang H, et al. 2022. Immunol Cell Biol. 100:547. PubMed
  130. Zhao Z, et al. 2022. Adv Sci (Weinh). 9:e2201293. PubMed
  131. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  132. Balood M, et al. 2022. Nature. 611:405. PubMed
  133. Xu H, et al. 2022. Aging Dis. 13:1875. PubMed
  134. Wang R, et al. 2023. iScience. 26:105954. PubMed
  135. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  136. Belk JA, et al. 2022. Cancer Cell. 40:768. PubMed
  137. Zhao L, et al. 2022. Oncogene. 41:4200. PubMed
  138. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  139. Sanmarco LM, et al. 2022. Nature. 611:801. PubMed
  140. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  141. Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed
  142. Li G, et al. 2023. Cell Death Dis. 14:185. PubMed
  143. Fan NW, et al. 2023. FASEB J. 37:e22855. PubMed
  144. Tang C, et al. 2023. Nat Commun. 14:1493. PubMed
  145. Ye S, et al. 2023. Front Oncol. 13:1202750. PubMed
RRID
AB_315399 (BioLegend Cat. No. 505805)
AB_315400 (BioLegend Cat. No. 505806)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account